Examining Isoniazid Dosage in Adults with Tuberculosis
Relevance of Isoniazid Dosage in Adults Treated for Tuberculosis
This study is trying to see how different doses of isoniazid affect adults with tuberculosis to make sure they get the right amount and avoid side effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 138 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens, Picardie) |
| Trial ID | NCT06054334 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relevance of isoniazid dosage in adults diagnosed with tuberculosis. It aims to assess the variability in isoniazid metabolism among individuals, focusing on the risks of hepatotoxicity and neurotoxicity associated with improper dosing. By measuring serum isoniazid levels and understanding the kinetics of its elimination, the study seeks to identify the proportion of patients receiving standard doses and the implications of potential overdosing or underdosing. The findings could provide valuable insights into optimizing tuberculosis treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are adults who have been diagnosed with tuberculosis.
Not a fit: Patients who are pregnant or unwilling to participate in the study may not receive any benefit.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment regimens for tuberculosis patients, reducing the risk of adverse effects.
How similar studies have performed: While there is limited data on isoniazid acetylation, similar studies on drug metabolism and personalized medicine have shown promise in improving treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * to be an adult, * to have a diagnosis of tuberculosis Exclusion Criteria: * pregnancy, * disagreement to participate
Where this trial is running
Amiens, Picardie
- CHU Amiens Picardie — Amiens, Picardie, France (Recruiting)
Study contacts
- Study coordinator: Claire ANDREJAK, Pr
- Email: andrejak.claire@chu-amiens.fr
- Phone: 03 22 08 79 98
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.